MT-125, a selective inhibitor of non-muscle myosin II, targets glioblastoma's tumor proliferation and resistance mechanisms. The FDA's fast track designation aims to expedite MT-125's development and ...
JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U ...
JUPITER, Fla., Oct. 22, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results